Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells
Both sorafenib and interleukin-27 (IL-27) are antineoplastic drugs. This study aimed to investigate the synergistic effect of these two drugs on bladder cancer cells. HTB-9 and T24 cells were stimulated with IL-27 (50 ng/mL), sorafenib (2 μM) or the synergistic action of these two drugs. The cells w...
Main Authors: | J.Y. Cao, H.S. Yin, H.S. Li, X.Q. Yu, X. Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Associação Brasileira de Divulgação Científica
|
Series: | Brazilian Journal of Medical and Biological Research |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000800610&lng=en&tlng=en |
Similar Items
-
Ellagic acid inhibits tumor growth and potentiates the therapeutic efficacy of sorafenib in hepatocellular carcinoma
by: Zhenju Tan, et al.
Published: (2024-01-01) -
MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway
by: Jing Ren, et al.
Published: (2023-05-01) -
Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma
by: Ruiqi Zheng, et al.
Published: (2023-01-01) -
Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro
by: Hui Xie, et al.
Published: (2022-09-01) -
Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death
by: Tarek El-Sewedy, et al.
Published: (2023-09-01)